Navigation Links
Codexis, Teva in Licensing Agreement Final
Date:1/7/2009

REDWOOD CITY, Calif., Jan. 7 /PRNewswire/ -- Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United States.

Under the agreement, Teva would be using the Codexis process for key process steps in the manufacture of this product, assuming technical milestones are met. Codexis develops proprietary custom biocatalysts, and its technology contributes to lower pharmaceutical process development and manufacturing costs. Codexis technology is in use by leading drug companies worldwide. Financial terms were not disclosed.

"Codexis is very pleased to be partnering with Teva, providing high value technology in the extremely cost-competitive generics marketplace," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer. "Our proven technology reduces the cost of pharmaceutical process development and manufacturing, and provides our partners with a significant competitive advantage as they respond to increasing market demands for lower cost pharmaceuticals."

Codexis, Inc. is a clean technology company. Codexis develops biocatalysts used to create powerful, efficient and cleaner chemistry-based manufacturing processes in the life sciences, bioindustrial and chemical marketplaces. Codexis technology is used by global pharmaceutical companies for cost-effective manufacturing of human therapeutics and in the energy industry to enable next generation non-food biofuels. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit http://www.codexis.com .

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, FRB, ssidenfaden@frbir.com, 212-827-3771.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis, Arch Announce Expanded Collaboration
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology
4. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
9. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
10. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
11. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Boston, MA (PRWEB) , ... ... ... Innovation, a commercial provider of distributed wastewater treatment and resource recovery solutions, ... install Cambrian’s award-winning EcoVolt® solution. The solution will provide Rombauer with the ...
(Date:1/24/2017)... CLARA, Calif. , Jan. 24, 2017  Frost & Sullivan ... of the Fonar Corporation, will receive special recognition at the ... taking place March 19 to 21, 2017 at the Loews Coronado ... To register and download the event agenda for Medical ... www.frost.com/medtech ...
(Date:1/24/2017)... Mass. , Jan. 24, 2017 /PRNewswire/ ... Hysitron, Inc., a technology leader in the ... instrumentation. The acquisition adds Hysitron,s innovative nanomechanical ... atomic force microscopes (AFMs), surface profilometers, and ... Bruker,s leadership position in nanomaterials research markets. ...
(Date:1/24/2017)... ... January 24, 2017 , ... Men who have ... levels had a positive association with increased prostate growth or benign prostatic hyperplasia, ... Neurourology Journal involved 571 Korean men who underwent urological examinations, including serum ...
Breaking Biology Technology:
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms ... from 2016 to 2021. The market is estimated to be USD ... by 2021. The growth of the biometric vehicle access system market ...
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
Breaking Biology News(10 mins):